Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 19;54(3):1900161.
doi: 10.1183/13993003.00161-2019. Print 2019 Sep.

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

Lutz Wollin  1 , Jörg H W Distler  2 , Elizabeth F Redente  3 , David W H Riches  3   4 , Susanne Stowasser  5 , Rozsa Schlenker-Herceg  6 , Toby M Maher  7   8 , Martin Kolb  9
Affiliations
Review

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

Lutz Wollin et al. Eur Respir J. .

Abstract

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the pathogenic mechanisms that drive disease worsening. Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD). In vitro data demonstrate that nintedanib inhibits several steps in the initiation and progression of lung fibrosis, including the release of pro-inflammatory and pro-fibrotic mediators, migration and differentiation of fibrocytes and fibroblasts, and deposition of extracellular matrix. Nintedanib also inhibits the proliferation of vascular cells. Studies in animal models with features of fibrosing ILDs such as IPF, SSc-ILD, rheumatoid arthritis-ILD, hypersensitivity pneumonitis and silicosis demonstrate that nintedanib has anti-fibrotic activity irrespective of the trigger for the lung pathology. This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patients with progressive fibrosing ILDs other than IPF (INBUILD) will report results in 2019.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L. Wollin is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. Conflict of interest: J.H.W. Distler has nothing to disclose. Conflict of interest: E.F. Redente has nothing to disclose. Conflict of interest: D.W.H. Riches has nothing to disclose. Conflict of interest: S. Stowasser is an employee of Boehringer Ingelheim International GmbH. Conflict of interest: R. Schlenker-Herceg is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB; has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB; and has received consultancy fees from Galecto. Conflict of interest: M. Kolb reports grants and personal fees for consultancy and lecturing from Roche and Boehringer Ingelheim, grants and personal fees for consultancy from GSK, Gilead and Prometic, grants from Actelion, Respivert, Alkermes and Pharmaxis, personal fees for consultancy from Genoa, Indalo and Third Pole, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Mechanisms known to be involved in the pathogenesis and progression of fibrosing interstitial lung diseases. EMT: epithelial–mesenchymal transition; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor; MVE: microvascular epithelium; FMT: fibroblast–myofibroblast transition; ECM: extracellular matrix. Tissue damage may occur at the alveolar epithelial and/or microvascular endothelial sites. Fibroblasts are recruited from resident fibroblasts, circulating fibrocytes, and epithelial cells and fibrocytes undergoing EMT. Growth factors are released by the damaged epithelium and endothelium, and leukocytes are recruited. Mononuclear cells and T-cells release pro-fibrotic mediators. Activated fibroblasts transition to myofibroblasts (FMT), which release excessive amounts of ECM. This results in increased tissue stiffness, which further stimulates fibroblast activation, leading to self-sustaining fibrosis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Travis WD, Costabel U, Hansell DM, et al. . An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748. - PMC - PubMed
    1. Raghu G, Remy-Jardin M, Myers JL, et al. . Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68. - PubMed
    1. Wells AU, Brown KK, Flaherty KR, et al. . What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692. - PubMed
    1. Jegal Y, Kim DS, Shim TS, et al. . Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639–644. - PubMed
    1. Zamora-Legoff JA, Krause ML, Crowson CS, et al. . Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2017; 69: 542–549. - PMC - PubMed

MeSH terms

  NODES
INTERN 6
twitter 2